Do analysts recommend THAR or ENTA?

Enanta Pharmaceuticals has a consensus target price of $20.29, indicating a potential upside of 34.25%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has stronger earnings and valuation, EPRX or THAR?

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A Tharimmune N/A N/A -$12.20M -$3.99 N/A

Is EPRX or THAR more profitable?

Eupraxia Pharmaceuticals' return on equity of -87.56% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -87.56% -51.20% Tharimmune N/A -588.45% -264.41%

Do analysts rate THAR or KMDA?

Kamada has a consensus price target of $12.00, suggesting a potential upside of 60.00%. Given Kamada's stronger consensus rating and higher probable upside, analysts clearly believe Kamada is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kamada 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better earnings and valuation, THAR or KMDA?

Kamada has higher revenue and earnings than Tharimmune. Tharimmune is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Kamada $181.68M 2.37 $20.20M $0.35 21.43

Is THAR or KMDA more profitable?

Kamada has a net margin of 11.21% compared to Tharimmune's net margin of 0.00%. Kamada's return on equity of 7.73% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Kamada 11.21% 7.73% 5.41%

Do analysts rate THAR or IPSC?

Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 95.47%. Given Century Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Century Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Is THAR or IPSC more profitable?

Century Therapeutics' return on equity of -49.89% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Century Therapeutics N/A -49.89% -37.42%

Do analysts rate THAR or PRTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, THAR or PRTC?

Tharimmune has higher earnings, but lower revenue than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Is THAR or PRTC more profitable?

PureTech Health's return on equity of 0.00% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% PureTech Health N/A N/A N/A

Tharimmune (THAR) Competitors

$2.84 -0.10 (-3.40%)

As of 07/2/2026

Compare

THAR vs. ENTA, EPRX, KMDA, IPSC, and PRTC

Should you buy Tharimmune stock or one of its competitors? MarketBeat compares Tharimmune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tharimmune include Enanta Pharmaceuticals (ENTA), Eupraxia Pharmaceuticals (EPRX), Kamada (KMDA), Century Therapeutics (IPSC), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry.

How does Tharimmune compare to Enanta Pharmaceuticals?

Tharimmune (NASDAQ:THAR) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Tharimmune has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Enanta Pharmaceuticals' return on equity of -64.04% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

Tharimmune has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Enanta Pharmaceuticals	$65.32M	6.73	-$81.89M	-$2.59	N/A

Enanta Pharmaceuticals has a consensus target price of $20.29, indicating a potential upside of 34.25%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Tharimmune's average media sentiment score of 0.00 equaled Enanta Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Tharimmune	Neutral
Enanta Pharmaceuticals	Neutral

Summary

Enanta Pharmaceuticals beats Tharimmune on 9 of the 13 factors compared between the two stocks.

How does Tharimmune compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

1.2% of Tharimmune shares are held by institutional investors. 6.7% of Tharimmune shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Eupraxia Pharmaceuticals' return on equity of -87.56% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
Tharimmune	N/A	-588.45%	-264.41%

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

In the previous week, Eupraxia Pharmaceuticals' average media sentiment score of 0.00 equaled Tharimmune'saverage media sentiment score.

Company	Overall Sentiment
Eupraxia Pharmaceuticals	Neutral
Tharimmune	Neutral

Eupraxia Pharmaceuticals presently has a consensus target price of $18.00, suggesting a potential upside of 169.06%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Eupraxia Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Summary

Eupraxia Pharmaceuticals beats Tharimmune on 7 of the 12 factors compared between the two stocks.

How does Tharimmune compare to Kamada?

Tharimmune (NASDAQ:THAR) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 6.7% of Tharimmune shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tharimmune has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Kamada has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

Kamada has a net margin of 11.21% compared to Tharimmune's net margin of 0.00%. Kamada's return on equity of 7.73% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Kamada	11.21%	7.73%	5.41%

In the previous week, Kamada had 2 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for Kamada and 0 mentions for Tharimmune. Kamada's average media sentiment score of 0.10 beat Tharimmune's score of 0.00 indicating that Kamada is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Kamada	Neutral

Kamada has a consensus price target of $12.00, suggesting a potential upside of 60.00%. Given Kamada's stronger consensus rating and higher probable upside, analysts clearly believe Kamada is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kamada has higher revenue and earnings than Tharimmune. Tharimmune is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Kamada	$181.68M	2.37	$20.20M	$0.35	21.43

Summary

Kamada beats Tharimmune on 14 of the 15 factors compared between the two stocks.

How does Tharimmune compare to Century Therapeutics?

Tharimmune (NASDAQ:THAR) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Century Therapeutics has higher revenue and earnings than Tharimmune. Century Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Century Therapeutics	$109.16M	4.01	-$9.58M	-$1.14	N/A

Tharimmune has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market.

1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Century Therapeutics' return on equity of -49.89% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Century Therapeutics	N/A	-49.89%	-37.42%

Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 95.47%. Given Century Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Tharimmune's average media sentiment score of 0.00 beat Century Therapeutics' score of -0.63 indicating that Tharimmune is being referred to more favorably in the media.

Company	Overall Sentiment
Tharimmune	Neutral
Century Therapeutics	Negative

Summary

Century Therapeutics beats Tharimmune on 10 of the 13 factors compared between the two stocks.

How does Tharimmune compare to PureTech Health?

Tharimmune (NASDAQ:THAR) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by company insiders. Comparatively, 5.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PureTech Health's return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
PureTech Health	N/A	N/A	N/A

Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

In the previous week, PureTech Health had 2 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for PureTech Health and 0 mentions for Tharimmune. PureTech Health's average media sentiment score of 0.30 beat Tharimmune's score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
PureTech Health	Neutral

Tharimmune has higher earnings, but lower revenue than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Summary

PureTech Health beats Tharimmune on 5 of the 9 factors compared between the two stocks.

Get Tharimmune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

THAR vs. The Competition

Export

Metric	Tharimmune	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$107.15M	$3.76B	$7.17B	$12.47B
Dividend Yield	N/A	2.16%	2.67%	6.50%
P/E Ratio	-0.71	21.80	27.81	24.70
Price / Sales	N/A	324.79	533.83	98.64
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	4.18	8.66	10.96	6.46
Net Income	-$12.20M	$23.81M	$3.57B	$337.01M
7 Day Performance	-4.38%	3.39%	2.11%	1.70%
1 Month Performance	19.83%	6.15%	2.80%	0.68%
1 Year Performance	54.68%	62.61%	33.39%	23.93%

Tharimmune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
THAR Tharimmune	N/A	$2.84 -3.4%	N/A	+54.7%	$107.15M	N/A	N/A	2
ENTA Enanta Pharmaceuticals	1.4565 of 5 stars	$15.13 +2.4%	$20.29 +34.1%	+91.5%	$439.98M	$65.32M	N/A	160
EPRX Eupraxia Pharmaceuticals	2.0046 of 5 stars	$6.68 -0.4%	$18.00 +169.5%	+22.4%	$434.33M	N/A	N/A	29
KMDA Kamada	4.9741 of 5 stars	$7.54 +0.3%	$12.00 +59.2%	-3.3%	$433.57M	$180.46M	21.54	360	News Coverage
IPSC Century Therapeutics	1.7264 of 5 stars	$2.39 -0.2%	$4.75 +99.2%	+333.9%	$429.77M	$109.16M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:THAR) was last updated on 7/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tharimmune (THAR) Competitors

THAR vs. ENTA, EPRX, KMDA, IPSC, and PRTC

How does Tharimmune compare to Enanta Pharmaceuticals?

Summary

How does Tharimmune compare to Eupraxia Pharmaceuticals?

Summary

How does Tharimmune compare to Kamada?

Summary

How does Tharimmune compare to Century Therapeutics?

Summary

How does Tharimmune compare to PureTech Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

THAR vs. The Competition

Tharimmune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tharimmune (THAR) Competitors

THAR vs. ENTA, EPRX, KMDA, IPSC, and PRTC

How does Tharimmune compare to Enanta Pharmaceuticals?

Which has more volatility & risk, THAR or ENTA?

Do institutionals & insiders have more ownership in THAR or ENTA?

Is THAR or ENTA more profitable?

Which has better valuation & earnings, THAR or ENTA?

Do analysts recommend THAR or ENTA?

Does the media prefer THAR or ENTA?

Summary

How does Tharimmune compare to Eupraxia Pharmaceuticals?

Do insiders and institutionals hold more shares of EPRX or THAR?

Is EPRX or THAR more profitable?

Which has stronger earnings and valuation, EPRX or THAR?

Does the media favor EPRX or THAR?

Do analysts prefer EPRX or THAR?

Which has more risk and volatility, EPRX or THAR?

Summary

How does Tharimmune compare to Kamada?

Do institutionals & insiders believe in THAR or KMDA?

Which has more risk and volatility, THAR or KMDA?

Is THAR or KMDA more profitable?

Does the media prefer THAR or KMDA?

Do analysts rate THAR or KMDA?

Which has better earnings and valuation, THAR or KMDA?

Summary

How does Tharimmune compare to Century Therapeutics?

Which has higher earnings & valuation, THAR or IPSC?

Which has more volatility & risk, THAR or IPSC?

Do insiders and institutionals hold more shares of THAR or IPSC?

Is THAR or IPSC more profitable?

Do analysts rate THAR or IPSC?

Does the media refer more to THAR or IPSC?

Summary

How does Tharimmune compare to PureTech Health?

Do insiders & institutionals hold more shares of THAR or PRTC?

Do analysts rate THAR or PRTC?

Is THAR or PRTC more profitable?

Which has more risk and volatility, THAR or PRTC?

Does the media refer more to THAR or PRTC?

Which has preferable valuation & earnings, THAR or PRTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

THAR vs. The Competition

Tharimmune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools